Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 18/20 | 0.62 |
| ▸ | MMP13 | P45452 | 14/20 | 0.62 |
| ▸ | MMP1 | P03956 | 10/20 | 0.62 |
| ▸ | MMP9 | P14780 | 7/20 | 0.62 |
| ▸ | MMP2 | P08253 | 4/20 | 0.51 |
| ▸ | MMP14 | P50281 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3948423 | 0.95 | ADAM17 (0.68) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL3949527 | 0.88 | ADAM17 (0.62) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6267645 | 0.82 | ADAM17 (0.62) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL7394890 | 0.77 | ADAM17 (0.52) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6265558 | 0.77 | ADAM17 (1.00) | ADAM17MMP13MMP1MMP9 | |
| SCHEMBL3949307 | 0.76 | MMP13 (0.67) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6268549 | 0.74 | ADAM17 (0.52) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6268734 | 0.73 | ADAM17 (0.76) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6263128 | 0.73 | ADAM17 (0.55) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL3948394 | 0.73 | ADAM17 (0.67) | ADAM17MMP13MMP1MMP9MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1147085-A1 | ALKYNYL CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS / TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITORS | American Cyanamid Company (US) | 2001-10-24 | — | — | EP | claimed |
| WO-2000044723-A1 | ALKYNYL CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS/TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | claimed |
| US-20040063672-A1 | Method for the treatment of polycystic kidney disease | WYETH HOLDINGS CORPORATION | 2004-04-01 | — | — | US | disclosed |
| EP-1147085-A1 | ALKYNYL CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS / TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITORS | American Cyanamid Company (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000044723-A1 | ALKYNYL CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS/TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063672-A1 | Method for the treatment of polycystic kidney disease | PKD1, PKD2, PCSK6 | ADAM17 9/4885MMP13 246/4885MMP1 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.